Immune rejection in a humanized model of murine prostate cancer (original) (raw)

MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment

Gail Prins

Prostate, 2006

View PDFchevron_right

HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy

Azizul Haque, Bently Doonan

The Open Cancer Immunology Journal, 2010

View PDFchevron_right

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen

Grete Sønderstrup

PubMed, 2003

View PDFchevron_right

Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy

Magnus Essand

The Prostate, 2007

View PDFchevron_right

Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design

Bently Doonan

2016

View PDFchevron_right

Recognition of Six-Transmembrane Epithelial Antigen of the Prostate–Expressing Tumor Cells by Peptide Antigen–Induced Cytotoxic T Lymphocytes

Sherine Elsawa

Clinical Cancer Research, 2005

View PDFchevron_right

Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes

Richard Barth

Cancer Immunology, Immunotherapy, 1996

View PDFchevron_right

Mouse hepa-1 tumor is rejected by H-2db-restricted CTL despite decreased MHC class I antigen expression

S. Ostrand-rosenberg

Cellular Immunology, 1991

View PDFchevron_right

MHC class I antigens, immune surveillance, and tumor immune escape

Angel Garcia

Journal of Cellular Physiology, 2003

View PDFchevron_right

A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity

Tamson Moore

Cancer Letters, 2005

View PDFchevron_right

Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy

Richard Barth

Proceedings of the National Academy of Sciences, 1997

View PDFchevron_right

Running Title: Selection of Antigen-negative Tumor Cells in the Prostate

Jianzhu Chen

2016

View PDFchevron_right

Rejection of allogeneic tumor is not determined by host responses to MHC class I molecules and is mediated by CD4−CD8+ T lymphocytes that are not lytic for the tumor

S. Ostrand-rosenberg

Cellular Immunology, 1991

View PDFchevron_right

The HLA crossroad in tumor immunology

ignacio algarra

Human Immunology, 2000

View PDFchevron_right

Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells

Lars Kaestner

International Journal of Cancer, 2008

View PDFchevron_right

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape

ignacio algarra

Cancer Immunology Immunotherapy, 2004

View PDFchevron_right

Histocompatibility Antigens on Murine Tumors

Richard Linsk

Science, 1985

View PDFchevron_right

Combination Immunotherapy of Primary Prostate Cancer in a Transgenic Mouse Model Using CTLA-4 Blockade1

Sang Truong

Cancer Research, 2000

View PDFchevron_right

The shared tumor‐specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection

Benoit Van den Eynde, Janine Bilsborough

European journal of …, 1998

View PDFchevron_right

Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade of B7-H1

Wenbo Ma

Journal of Clinical Immunology, 2006

View PDFchevron_right

Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells

Bently Doonan

International Journal of Molecular Sciences

View PDFchevron_right

IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer

M. Colombatti, Silvia Sartoris, Giulio Innamorati, Matteo Pasetto

2010

View PDFchevron_right

Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer

David Cosman

Journal of Clinical Investigation, 2004

View PDFchevron_right

Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens

Masoud Manjili

Cancer Immunology, Immunotherapy, 2011

View PDFchevron_right

David Escors

View PDFchevron_right

New strategy for the identification of squamous carcinoma antigens that induce therapeutic immune responses in tumor-bearing mice

amla Chopra

Cancer Gene Therapy, 2007

View PDFchevron_right

Immune rejection in a humanized model of murine prostate cancer (original) (raw)

Related papers